RxDoctor Payments Data

Kirk Minkus, MD

Vascular & Interventional Radiology · Mesa, AZNPI 1164494746

Payments from drug & device makers

What this record shows

Medtronic accounts for 64.2% of it on its own, with 38 other manufacturers making up the rest. 2025 is the largest year on record at $10,415, 5.0 times the $2,091 reported in 2019.

$18,840in general payments, 2019–2025

Across 328 payments — averaging $57.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$12K
  • Philips North America LLC$938
  • Siemens Medical Solutions USA, Inc.$801
  • Johnson & Johnson$553
  • Impulse Dynamics (USA) Inc.$523
  • Abbott$491
  • plus $3K from 33 others
$9,750in research payments, 2019–2025

Across 1 payment — averaging $9750.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Philips North America LLC$10K

What the payments were for

  • Travel & lodging$8,91147%
  • Food & beverage$9,92953%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$18,840 in reported general payments places this provider in the 80th percentile of 80 vascular & interventional radiology providers in Arizona.

See all vascular & interventional radiology providers in Arizona

Medicare billing

Part B allowed, 2024
$984,525
Medicare patients
490
Services billed
2,457

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban35$30,818
XareltoRivaroxaban26$21,191
ClopidogrelClopidogrel Bisulfate141$1,964
Cilostazol15$409
Furosemide14$115

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$148$30,81835 claims
Johnson & JohnsonXarelto$553$21,19126 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 80 vascular & interventional radiology providers in Arizona.

Other vascular & interventional radiology in Mesa

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →